Informasjon/Twitter/Artikler/Børsmeldinger


Jeg vet at mange har interesse av å følge med på utviklingen i Photocure. Og for dem som eventuelt ikke er medlem i vår Facebook gruppe skal jeg også publisere her innimellom. Dersom dere ønsker å diskutere noe av det som blir delt her kan dere gjøre det på andre tråder.
Erfaringsmessig blir enhver PHO tråd ødelagt ganske umiddelbart så jeg holder den åpen kun for lesetilgang.
Forøvrig er dere hjertelig velkommen inn i FB gruppen som nå teller hele 599 medlemmer.
Det finnes 3273 aksjonærer i Photocure så det er plass til flere i gruppen.

Starter med et lite utvalg av delingene på fb gruppen siste uken.

PS! FB gruppen har nå 785 medlemmer!, den 22.8. 30.9 har den 814.


https://twitter.com/Cysview/status/1139565681874223105

http://santansun.com/2019/06/13/gilberts-md-anderson-center-celebrates-survivors/?fbclid=IwAR3w248nRjxHfZ8Zb1C9-FGAEJL4vIXLTMbOADei7oIoHooB4SIJUwZzcIU

https://www.youtube.com/watch?v=AQCSH005uDs&fbclid=IwAR1M0zvb7he1ikyc7U6Bor3T4Tjhf1BfLkJJmnL7myLQdFzM8CM0o-qV9M0

https://finance.yahoo.com/news/why-photocure-asa-ob-pho-120355805.html?guce_referrer=aHR0cHM6Ly90ZWtpbnZlc3Rvci5uby8&guce_referrer_sig=AQAAAN1bXZLFh3xYZBPzMKtz4JpEyTxNURdI7tWOsZyP8CcFouBFik2iBwjFLBhuAduKZ4xjJpIbGqQ7lZspb9lLvZ44wdtmZhik79grZWWYVAD5SvQ1v2rfqCbtGOH5nSHLiqcRFSlOolw2BHh2m1B-keblOZk2OMtU0Nd73tCD2OzZ&guccounter=2

https://www.sciencedirect.com/topics/medicine-and-dentistry/cystoscopy?fbclid=IwAR3W1N0UZMYb4zVQ_0X2S3G4X46NYqA53ShEqAzvTZLo7qfdDALItsApCvM

https://www.mdlinx.com/journal-summaries/urothelial-carcinoma-in-situ-blue-light/2019/06/10/7569052/?spec=urology&fbclid=IwAR2xAB2LFKvvOIHC0h2zuSOrH50pHGXCJDV5hpq_66RZlXYp6eK3QUBLMR8

https://twitter.com/PhotocureASA/status/1138507513077403649

https://www.bcan.org/wp-content/uploads/2019/06/Recurrence-and-Prevention-Transcript.pdf?fbclid=IwAR3IkuPa34ZCxtyBA5LBZRlPBQvfhtz_T3UsynZx_ARWvJ2sQChY05Aqz14


Redigert 30.09.2019 kl 18:58 Du må logge inn for å svare

“This technique is game-changer when it comes to keeping a close watch on bladder cancer,” said Gennady Bratslavsky, MD, professor, and chair of Upstate’s Department of Urology. “We now have a supercharged cystoscopy technique that highlights cancerous tumors as we have never seen them before.”

https://cnycentral.com/news/local/upstate-cancer-center-introduces-new-technology-to-detect-bladder-cancer
Redigert 21.08.2019 kl 21:59 Du må logge inn for å svare

Slik ser det ut når en går inn på hjemmesiden til Upstate Cancer Center og finner Bladder Cancer Program. Veldig bra!

http://www.upstate.edu/cancer/cancer-care/programs/bladder/blc.php

Litt mye om Upstate Cancer Center, men det gir hvertfall omtale og er det noe vi trenger er det omtale i tillegg til at klinikken er stolt av det nye verktøyet sitt.

https://www.cnybj.com/upstate-cancer-center-deploys-new-technology-to-combat-bladder-cancer/

Radium Podcast nummer 89.
Photocure fra 20:50

Einarsson mener at Cevira avtalen kom som lyn fra klar himmel og gir Schneider æren for dette innledningsvis.
Sign on fee, samt her kan det komme penger i kassen fortløpende. Her går det liksom ikke 10 år før en får penger i kassen.
Q2. Nær monopol situasjon. Ingen synlige konkurrenter. Nesten break even, inntektene stiger, kostnadene flater ut, Einarsson holder fast ved at selskapet snart tar av. Framover nå må det bare bli pluss.
https://soundcloud.com/user-972208711/episode-89?fbclid=IwAR2EPbNQVeLIgrfppylrliTsFJV8Se507DtK0hlALQ6VjAdtSh6bXXYzkXk

Klinikk nummer 128 og 129 er lagt til på Cysview

LSU Health Network | Metairie Multi-Specialty Clinic-Urology
Scripps Green Hosptial

https://www.cysview.com/about/where-its-available/?locate=
Redigert 23.08.2019 kl 22:32 Du må logge inn for å svare

Oppdatert Topp 20 som øker med ca. 7k totalt.

Altså små bevegelser fortsatt.

https://photocure.com/investor/largest-shareholders/


Denne er også ny og kan faktisk ikke se at denne heller er oppført på Cysview.
Her snakker vi såvidt jeg kan se også flexiskop.
"“At University Urology, patients with known or suspected bladder cancer can now undergo diagnostic procedures performed by physicians who have been specially trained in the use of this innovative technology,” Terry said. “We are also able to perform BLC and bladder biopsies in the office setting, if needed.”

https://www.usahealthsystem.com/news/university-urology-blue-light

Klinikk nummer 131 oppført på Cysview.com nå.

Lahey Hospital and Medical Center
Redigert 13.09.2019 kl 16:37 Du må logge inn for å svare

Klinikk nummer 132 oppført på Cysview.com nå.

Montrose Memorial Hospital
Redigert 13.09.2019 kl 19:45 Du må logge inn for å svare

Klinikk nummer 133 oppført på Cysview.

St. Mary’s Medical Center

https://www.cysview.com/about/where-its-available/?locate=
Redigert 14.09.2019 kl 09:14 Du må logge inn for å svare

Oppdatert Topp 20 som øker litt gjennom forrige uke.

Nordnet Liv + ca. 25k

Fondsfinans Global Helse + ca. 10k

https://photocure.com/investor/largest-shareholders/

Klinikk nummer 134 oppført på Cysview.

Prestige Medical Group 720 N. Tustin Ave, Suite 104 Santa Ana, CA 92705

Klinikk nummer 135 oppført på Cysview.

Reston Hospital Center, 1850 Town Center Pkwy, Reston, VA 20190

Kan være den samme som denne, har ikke fått sjekket grundig nok enda:

AndyHagen
12.09.2019 kl 21:04
1377
Ny klinikk med BLC, Reston Hospital Center. Ikke oppført på Cysview.

https://www.biospace.com/article/reston-hospital-first-in-northern-virginia-to-offer-innovative-procedure-to-improve-detection-of-certain-bladder-cancers/?fbclid=IwAR12vwFBwOSOYQx2kZYm9zy_0K4lryK8R_lYxn39alR0LPZ6K6TJB0j6QFE
Redigert 26.09.2019 kl 08:01 Du må logge inn for å svare

https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-1007-8497

Abstract

Background Photodynamic Diagnosis (PDD) is widely used today for the diagnosis and treatment of superficial bladder cancer. This study aimed to analyse the impact of using this technique on recurrence rate, residual tumour rate and progression-free survival.

Materials and methods We conducted this study retrospectively in our unit between 10/2014 and 02/2018. We divided our patients into 2 groups: white light group, 49 patients who underwent primary bladder tumour resection with white light transurethral resection of bladder tumour (WL-TURB), and blue light group, 49 patients treated with blue light transurethral resection of bladder tumour (BL-TURB) with PDD. Patients in both groups were followed up for one year. We collected data for tumour recurrence for the first year, 3-month and 1-year relapse-free survival and 1-year progression-free assessment pursuant to the EORTC risk classification by Sylvester 2006. Furthermore, the residual tumour rate was determined by re-TURB.

Results The following results were found independent of age, gender and histological findings: Residual tumour rate: blue light group 13.95 % vs. white light group 32.6 %, (p 0.02, OR 3.8, CI 95 % [1.17 – 12.85]).; 3-month relapse-free survival: blue light group 87.7 % vs. white light group 67.4 % (p 0.02, HR 3.18, CI 95 % [1.20 – 8.42]); 1-year relapse-free survival: blue light group 77.6 % vs. white light group 55.1 % (p 0.015, HR 2.56, CI 95 % [1.20 – 5.45]); 1-year progression-free survival: blue light group 95.9 % vs. white light group 79.6 %, p 0.03, HR 5.23, CI 95 % [1.11 – 24.53])

Conclusion The use of hexaminolevulinate significantly reduces the risk of residual tumours compared with conventional TURB. The PDD technique significantly improved 3- and 12-month recurrence-free survival, especially in low and medium-risk tumours, and 1-year progression-free survival, especially in high-risk tumours

Klinikk nummer 136 oppført på Cysview.

VA Long Beach Healthcare System
5901 East 7th Street Long Beach, CA 90822
Redigert 27.09.2019 kl 21:37 Du må logge inn for å svare

Sometimes when we write stories, we have no idea who is impacted; other times, we are able to bring about change that we had no way of foreseeing.

In August 2018, I wrote a feature on Alex Huang, his battle with bladder cancer and his subsequent role as an ambassador for the greater Hamilton area with Bladder Cancer Canada. He was trying to promote the local support group available to other bladder cancer patients. Not only did the article help bring in some new members, but through one of those new members, Alex learned about blue-light cystoscopy, a new technology that is showing huge promise around the world as a better way to detect, and ultimately treat, bladder cancer. Now, Alex is working to get area hospitals to commit to bringing the technology here — and once they do, he’s ready to start fundraising, and I’m ready to write the update.

https://www.sachem.ca/news-story/9632150-sachem-and-gazette-stories-that-moved-our-journalists/

Oppdatert Topp 20.
De har totalt redusert med minus ca. 15k.
Endringer:
Frank Stave + 20k(Økt jevnt med ca 15-18k pr uke siste tre uker)
Fondsfinans - 15k
Nordnet Livsforsikring -20k
Danske Bank - 1k

https://photocure.com/investor/largest-shareholders/

Klinikk nummer 137 oppført på Cysview.

Brigham and Women's Faulkner Hospital
1153 Centre St, Boston, MA 02130
Redigert 14.10.2019 kl 15:38 Du må logge inn for å svare

For our in-licensed photodynamic product, Cevira®, it is actually a second-generation product. The first-generation product entered Phase II trials but was discontinued because it was not efficacious enough. The second-generation product has made improvement in design to increase its absorption, which should theoretically increase the sensitivity of the drug to photo-activation. In addition, the phototherapy device has been miniaturized so it can be implanted on the cervix. Patients can leave the hospital and remove the device easily by themselves once the treatment is completed. Importantly, the product has shown positive Phase II results, which finally gave us the confidence to invest.

https://pharmaboardroom.com/interviews/kevin-pan-ceo-asieris-china/?fbclid=IwAR2-oIWM8sEpFZOWBgpzjLOosf72ECSX7-1eq7eHZ3rOyS0Myd74z-fkcQ0

And this is not unique to this study either. We have seen the same thing with the flexible blue light study that we did where we were looking at detection of CIS with flexible blue lights, cystoscopy in the office. And we found the same thing, that cytology was not sensitive in picking up the high-grade cancers in many, many of the cases. In fact, all the lesions that were seen with blue light alone had negative cytology. So again, this is consistent with those results.

https://www.urotoday.com/video-lectures/bladder-cancer/video/mediaitem/1540-players-brightcove-net2019-10-15-19-14-58.html